In a recent article, Celgene CEO, Mark Alles, offered three proposals that would dramatically improve access and cost to innovative therapies for many Americans, particularly those with chronic diseases. Alles proposed removing regulatory barriers to value-based contracting, oral parity laws for oral anticancer medications, and patient protections for step therapy. Read more here.
Last Updated on May 13, 2020 by Aimed Alliance
